MarkRodgerSteinMD

Allergy & Immunology • North Palm Beach, FL

Physician

Join to view full profile

Dr. Stein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Stein's full profile

Already have an account?

Office
840 US Highway 1
Ste 235
North Palm Beach, FL 33408
Phone+1 561-626-2006

Fax+1 561-624-9718

Education & Training

Fitzsimons Army Medical CenterResidency, Internal Medicine, 1975 - 1977
Letterman Army Medical CenterResidency, Internal Medicine, 1972 - 1975
University of Colorado School of Medicine/National Jewish Health (Adult)Residency, Allergy and Immunology, 1968 - 1970
Abington Memorial HospitalInternship, Transitional Year, 1968 - 1969
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1968

Certifications & Licensure

CA State Medical License 1971 - Present
FL State Medical License 1979 - 2025
PA State Medical License 1969 - 1992
MD State Medical License 1977 - 1983
CO State Medical License 1975 - 1979
American Board of Allergy and Immunology Allergy & Immunology
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Top MD Consumers Checkbook
Whos Who in Medicine and Healthcare Marquis Whos Who
Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology

Clinical Trials

Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma Start of enrollment: 2008 Aug 18
Active, not recruiting
Phase 1
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2009 Jul 01
Completed
Phase 1
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases Start of enrollment: 2014 Feb 01
Completed
Phase 3

Publications & Presentations

PubMed

36 citations
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
Richard L. Wasserman, Isaac Melamed, Mark R. Stein, Werner Engl, Marlies Sharkhawy
Journal of Clinical Immunology. 2016-05-25
76 citations
Safety and Efficacy of Privigen®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies
Mark R. Stein, Robert P. Nelson, Joseph A. Church, Richard L. Wasserman, Michael Borte
Journal of Clinical Immunology. 2009-01-01
23 citations
Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses...
Richard L. Wasserman, William R. Lumry, James B. Harris, Robyn J. Levy, Mark R. Stein
Journal of Clinical Immunology. 2016-06-20

Press Mentions

CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients’ Previous Immunoglobulin TherapyMarch 6th, 2017
Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North AmericaMarch 7th, 2016

Professional Memberships

American Academy of Allergy Asthma and Immunology - AAAAI
Fellow